Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-10-06 pm EDT
1.830 USD   -1.08%
09/12Regulus Therapeutics Says Kidney Disease Drug Showed Favorable Safety Profile in Phase 1 Study
MT
09/12Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PR
09/12Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Regulus: Q2 Earnings Snapshot

08/11/2022 | 05:22pm EDT

SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $7.3 million in its second quarter.

On a per-share basis, the San Diego-based company said it had a loss of 50 cents.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about REGULUS THERAPEUTICS INC.
09/12Regulus Therapeutics Says Kidney Disease Drug Showed Favorable Safety Profile in Phase ..
MT
09/12Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data fr..
PR
09/12Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data fr..
CI
09/02Regulus Therapeutics to Participate in Upcoming Investor Conferences
PR
08/11Regulus : Q2 Earnings Snapshot
AQ
08/11Transcript : Regulus Therapeutics Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11REGULUS THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
08/11Regulus Therapeutics : Reports Second Quarter 2022 Financial Results and Recent Updates - ..
PU
08/11Earnings Flash (RGLS) REGULUS THERAPEUTICS Posts Q2 Loss $-0.50
MT
08/11Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
PR
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -28,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,07x
Yield 2022 -
Capitalization 26,8 M 26,8 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 26
Free-Float 86,4%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,83 $
Average target price 14,00 $
Spread / Average Target 665%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-41.27%27
REGENERON PHARMACEUTICALS, INC.18.08%79 719
VERTEX PHARMACEUTICALS37.53%77 456
BIONTECH SE-46.78%33 340
WUXI APPTEC CO., LTD.-39.54%29 208
GENMAB A/S1.14%22 982